Skip to main content
. 2016 Dec 21;6(12):e012690. doi: 10.1136/bmjopen-2016-012690

Figure 2.

Figure 2

Modelled rates* of AKI (during the calendar period 2012–2014) per 1000 person years at risk for AKI during time exposed to antihypertensive treatment including ACEI/ARB compared to time exposed to antihypertensive treatment excluding ACEI/ARB, stratified by characteristics and comorbidities. *Absolute rates (unless otherwise stated) are for men, aged 75–84, with CKD stage 3a, and no comorbidities—chosen as a large, clinically important, high-risk group. **Adjusted using Poisson regression for age, sex, chronic comorbidities (CKD, hypertension, diabetes mellitus, cardiac failure, ischaemic heart disease and arrhythmia), time exposed to other antihypertensive drugs (β blockers, calcium channel blockers and thiazides), time exposed to loop and potassium-sparing diuretics and calendar period. AKI, acute kidney injury; ACEI/ARB, ACE inhibitors inhibitor/angiotensin receptor blocker; pyar, Person years at risk; CKD, chronic kidney disease; ACEI/ARB exposed, antihypertensive treatment including ACEI/ARB; ACEI/ARB unexposed, antihypertensive treatment excluding ACEI/ARB; IRR, incidence rate ratio.